Andractim Gel

Andractim Gel is a prescription androgen medicine containing androstanolone, also known as dihydrotestosterone (DHT). The current French product information identifies Andractim as a 2.5% gel for local application, containing 2.50 g of androstanolone per 100 g of gel and supplied in an 80 g aluminium tube.

Andractim is an androgenic medicine with both systemic and local uses under its approved French labeling. Because regulatory approvals and indications vary by country, including the United States, the exact legal status and permitted use should be verified in the destination market.

Product Information

• Brand Name: Andractim
• Active Ingredient: Androstanolone
• Other Name: Dihydrotestosterone (DHT)
• Drug Class: Androgen
• Strength: 2.5% w/w
• Concentration: 2.50 g androstanolone per 100 g gel
• Dosage Form: Topical / Transdermal Gel
• Route: Cutaneous application
• Pack Size: 80 g tube
• Prescription Status: Prescription medicine in France
• Manufacturer / Authorization Holder: Besins Healthcare France
• Product Type: Branded medicinal product
• Active Ingredient Category: Androgenic hormone

Andractim vs Testosterone Gel

Andractim and conventional testosterone gels are not the same medicine.

Andractim Gel contains androstanolone / DHT.

Testosterone gels contain testosterone.

DHT and testosterone have different pharmacological characteristics and tissue effects. Andractim should therefore not be described as simply another brand of testosterone gel.

Andractim and DHT

Dihydrotestosterone is an endogenous androgen produced naturally in the human body, principally through the conversion of testosterone by the enzyme 5-alpha-reductase.

Androstanolone is the pharmaceutical form of DHT used in Andractim.

The 2.5% concentration refers to the amount of active androstanolone in the finished gel, not to testosterone concentration.

USA Regulatory Status

Andractim is associated primarily with non-U.S. markets, including France.

The current French public medicines database lists the product as authorized there. The United States has different regulatory requirements, and Andractim should not be described as an FDA-approved U.S. brand.

The FDA has records concerning dihydrotestosterone gel research/orphan designation, but an orphan designation is not the same as FDA approval.

U.S. customers should distinguish between an international product such as Andractim and FDA-approved androgen products available in the United States.

International Availability

Andractim’s regulatory status varies by country. A product being authorized in one jurisdiction does not establish approval, legal marketing status or prescription availability in another.

For international product searches, customers should verify:

• Exact active ingredient
• 2.5% concentration
• Manufacturer
• Tube size
• Country-specific authorization
• Prescription requirements
• Import regulations
• Product authenticity

Safety and Precautions

Andractim contains a potent androgen and requires appropriate medical supervision.

The French product information lists contraindications and precautions related to androgen therapy, including prostate cancer in men. It also warns about the potential for virilization in women receiving systemic androgen therapy.

Androgen treatment may also require consideration of cardiovascular, hepatic, renal and prostate-related risks depending on the patient and treatment context.

Andractim can also produce a positive anti-doping test because it contains an androgenic active substance.

Women who are pregnant or may become pregnant should not be exposed to androgen medicines without specialist medical direction because androgen exposure can produce virilizing effects.

Product Quality and Authentication

For Andractim Gel, important product-identification details include:

• Andractim brand name
• Androstanolone as active ingredient
• 2.5% strength
• 80 g tube
• Manufacturer / authorization-holder details
• Batch number
• Expiry date
• Original packaging
• Country-specific regulatory information

Because Andractim is a prescription androgen medicine, buyers should be particularly cautious with products presented as unofficial “DHT creams,” “DHT gels” or unverified copies.

Availability & Ordering

Search interest for this product includes Andractim Gel USA, Andractim Gel UK, Andractim 2.5% Gel, Andractim DHT Gel, Androstanolone Gel, Dihydrotestosterone Gel USA and Andractim Gel Australia.

Regulatory availability differs substantially between countries. Product pages should therefore distinguish the branded French medicine Andractim from compounded DHT products, testosterone gels and other androgen formulations.

Last Updated: September 20, 2026

Medical Disclaimer: This information is provided for educational and product-information purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Andractim is a prescription androgen medicine and may not be appropriate for everyone. Always consult a qualified healthcare professional and verify the regulatory status applicable in your country before use.

How it works

Androstanolone is a potent androgen and a form of dihydrotestosterone (DHT). DHT binds to androgen receptors and contributes to androgen-dependent biological processes in tissues that respond to male sex hormones.

Unlike testosterone, DHT is itself a 5-alpha-reduced androgen and does not require conversion to DHT to exert androgen-receptor activity.

Androgen-sensitive tissues can therefore respond directly to the active ingredient in Andractim Gel.

Under the current French product information, Andractim has both systemic and local therapeutic uses.

For adult men, its systemic indication includes androgen deficiencies, particularly hypogonadism, when testosterone deficiency has been clinically or biologically confirmed.

Its local indications include:

• Idiopathic gynecomastia in men
• Atrophic lichen sclerosus in men
• Vulvar lichen sclerosus in women

Possible adverse effects associated with androgen therapy vary according to dose, duration, indication and patient characteristics.

Potential issues can include:

• Acne and oily skin
• Changes in libido
• Changes in mood
• Androgen-related skin or hair effects
• Fluid retention
• Changes in blood-related laboratory parameters
• Prostate-related effects in men
• Virilization in women exposed to systemic androgen therapy

Any persistent, severe or unexpected adverse effect should be assessed by a healthcare professional.